CNSP — CNS Pharmaceuticals Share Price
Last trade - 00:00- $3.33m
- -$2.81m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.54 | ||
| Price to Tang. Book | 0.54 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -241.25% | ||
| Return on Equity | -1703.4% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 27th, 2017
- Public Since
- November 8th, 2019
- No. of Shareholders
- 5
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,944,381
- Address
- 2100 West Loop S Ste 900, HOUSTON, 77027-3522
- Web
- https://cnspharma.com/
- Phone
- Contact
- Jenene Thomas
- Auditors
- Malone Bailey, LLP
Latest News for CNSP
Upcoming Events for CNSP
Q1 2025 CNS Pharmaceuticals Inc Earnings Release
Q2 2025 CNS Pharmaceuticals Inc Earnings Release
Q2 2025 CNS Pharmaceuticals Inc Earnings Release
Similar to CNSP
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 20:00 UTC, shares in CNS Pharmaceuticals are trading at $1.13. This share price information is delayed by 15 minutes.
Shares in CNS Pharmaceuticals last closed at $1.13 and the price had moved by -99.79% over the past 365 days. In terms of relative price strength the CNS Pharmaceuticals share price has underperformed the S&P500 Index by -99.81% over the past year.
The overall consensus recommendation for CNS Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCNS Pharmaceuticals does not currently pay a dividend.
CNS Pharmaceuticals does not currently pay a dividend.
CNS Pharmaceuticals does not currently pay a dividend.
To buy shares in CNS Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.13, shares in CNS Pharmaceuticals had a market capitalisation of $3.33m.
Here are the trading details for CNS Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CNSP
Based on an overall assessment of its quality, value and momentum CNS Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in CNS Pharmaceuticals is $200.00. That is 17599.12% above the last closing price of $1.13.
Analysts covering CNS Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$42.13 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CNS Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -79.84%.
As of the last closing price of $1.13, shares in CNS Pharmaceuticals were trading -85.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CNS Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on CNS Pharmaceuticals' directors